Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Watcher's Thread / Pix of the Week (POW) -- Ignore unavailable to you. Want to Upgrade?

To: Stock Watcher who wrote (11458)	6/30/1999 11:07:00 AM
From: Mr.Manners	Read Replies (1) \| Respond to of 52051

HUMT.. new yr high.. one to watch, and check out Symbol- HUMT Shares Outstanding- 8,405,000 Float (est.)- 500,000 52 Week High/Low- 0.13- 1.43 6 mo. Target- 7 HumaTech Inc. (OTC BB: HUMT), our newest pick here at Investors' Alert, we adamantly believe will be our big winner of the year. HumaTech is a manufacturer and distributor of humate-based nutrients for both plants and animals. Its products are classified as High Technology Organic Solutions. Its products are created from a proprietary process known as Iso-Molecular Technology. HumaTech sells its proprietary product lines to Growers of Agricultural Crops, Golf Courses and Commercial Landscapers, Mass Merchandisers and Independent Nurseries for Lawns and Gardens, Animal Feed Supplements to Feedlots. The company has been manufacturing its products for over 20 years and is now dramatically increasing its revenues at an explosive rate. In fact, we have no doubt that HumaTech's revenues will surpass $8 million this year (a hair raising 1500% increase from 1998.) Management's own projections are $3.5 million to $8 million for 1999. HumaTech experiences extremely high gross and net margins. Net margins are 30% this fiscal year; and as soon as the company surpasses $50-60 million/year, margins will drop to approximately 25%, which is still extremely high. On $8 million in revenue, that gives the company a net profit of $2.4 million before tax. If the company trades at a very conservative P/E of 15, the stock should trade between $4.50-$5, and we are talking about only 6 months from now. Now that's exciting, a stock going from $1.25 to $5 in six months. But we believe this stock has the potential of $20 or higher in the next 8-10 months, and here is why: 1) HumaTech, on May 13th of this year, announced the signing of the services of Club Marketing of Duncanville TX, with the intention of introducing its new product line GreensKeeper STRONG BUY / AGRRESSIVE GROWTH (OTC BB: HUMT) Secret, to Wal-Mart, (NYSE: WMT) Home Depot, (NYSE: HD) and other mass market retailers for national distribution. We believe a contract will be signed with Wal-Mart very soon. That contract alone we believe will be worth in excess of $10 million/year. 2) Who can ever forget Mad Cow Disease? HumaTech is the only approved, worldwide solution. We believe HumaTech's solution will be highly publicized, and HumaTech will become one of this year's hottest stocks. On June 22nd, HumaTech announced it has received approval to import its entire line of natural feed ingredients into the European Union. The company has received full approval from the Ministries of Agriculture Fisheries and Food; HumaTech is the only company to receive this approval. This is very significant. HumaTech's products replace artificial growth hormones currently used in the animal feed market. These artificial growth hormones will be banned as of July 1999 in the entire E U. Mad Cow disease has been found attributable to the use of these artificial growth hormones. This is huge. The worldwide market for artificial hormones is $4 billion annually. Management has stated that this product line will generate $2 million in the following few months; but after interviewing management we believe HumaTech will generate $50-100 million/year, or more, with its natural feed ingredients in this market. Let us not forget about the United States. The USDA has already stated it will phase out the use of artificial growth hormones in the US. That is why we are putting our 6 mo. Target at $7 over $5, because of the incredable potential of this company we believe the stock will trade at a higher P/E multiple than 15. Investors' Alert is an independent research firm with paid subscribers. Subscriptions are $139.00/year for Investors' Alert newsletter service. This report is based on Investors' AIlert independent analysis but relies on information supplied by sources believed to be reliable, The information contained in this report is not intended to be, and shall not constitute, an offer to sell nor solicitation of any offer to buy any security. Thomas Loyd has purchased 45,000 shares of HUMT in the past 3 days, Thomas Loyd has also helped HUMT with corporate finance issues and Loyd Financial Consulting was paid $32, 000 of HUMT stock. Copyright © 1999 Loyd Financial Consulting. All rights reserved.

To: Stock Watcher who wrote (11458)	6/30/1999 11:17:00 AM
From: DR. MEADE	Respond to of 52051

SW, INDEX # 3 stock : ** APPI .048 x .05, News out ! ** Wednesday June 30, 10:30 am Eastern Time Company Press Release SOURCE: Advanced Plant Pharmaceuticals, Inc. Advanced Plant Pharmaceuticals Inc. - APPI - Signs Exclusive Distribution Agreement with Ambar Pharmacies and Health NEW YORK, June 30 /PRNewswire/ -- Advanced Plant Pharmaceuticals, Inc. (OTC Bulletin Board: APPI - news) a company that utilizes whole plants to develop all natural dietary supplements, signed an exclusive Distribution Agreement with Ambar Pharmacies and Health, Inc. in which Ambar agrees to distribute stated minimums of APPI's products in Israel. The exclusive agreement, APPI's first firm commitment from an overseas corporation, requires Ambar to purchase certain minimum quantities of APPI's dietary supplements, ''ACA'' and ''Lo-Chol.'' Ambar, which was established by Ambar Abraham a licensed pharmacist, and Dr. Reuven Barak M.D., distributes Chinese medicines and all natural products to pharmacies, hospitals, clinics, shops, and practitioners all over Israel. Ambar has the largest updated mailing list of practitioners with patients, most of which are working with Ambar. ''Your company holds a product, that the Israeli market requires,'' said Ambar Abraham, General Manager for Ambar. ''With our expertise, we will take responsibility for the marketing of your products.'' Mr. Abraham further stated, ''the advantage of us representing APPI is that we will exclusively focus on your products, in terms of bringing the sales to their maximum money potential.'' APPI, which is currently negotiating similar overseas distribution agreements, hopes that this agreement with Ambar will be the first of many distribution agreements. APPI, after several years of research and development, began marketing its products in January of this year. The company hopes to announce further agreements in the near future. Company information, and ordering of product can be obtained on APPI's Internet web site located at advancedplantpharm.com APPI is a company that develops innovative plant formulations and technology for clinical application. APPI has met FDA nutritional specifications for the marketing of its Cholesterol lowering agent ''Lo-Chol'' in the USA, and has received the first IND from the FDA for a whole plant pharmaceutical, Abavca/ACA, which has potential as an immunomodulater in the treatment of patients infected with HIV, the virus that causes AIDS. APPI's Whole Plant Pharmaceutical Grade Process is trade secret and patent pending. Utilization of the APPI process converts a whole plant into the best standardized pharmaceutical grade product. This press release contains forward-looking statements. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. CONTACT: Barry Clare of Advanced Plant Pharmaceuticals Inc., 212-402-7878; or Ambar Abraham of Ambar Pharmacies & Health, +972-3-75235543. SOURCE: Advanced Plant Pharmaceuticals, Inc.